Leaders in digital health development and regulation look at best practices, pitfalls and what’s next for connected medical devices and technologies.
By deploying connected intelligence systems at a global scale, teams can navigate go-to-market challenges by increasing the transparency and predictability of the complex and divergent global product registration processes.
Rama Chellappa, PhD, John Hopkins University Bloomberg Distinguished Professor in electrical, computer, and biomedical engineering, and co-author of “Can We Trust AI?” looks at the promise of AI in health care and how we can best utilize this extraordinary tool to save lives and improve health equity.
The FDA is asking stakeholders to submit public comments on how it should use any portion of the user fee funding that may be distributed to external organizations—other than NEST—to support premarket RWE in medical device evaluation and development.
Under the leadership of Jeff Thompson, MD, Gundersen Health System reduced its greenhouse gases by 95% and was nationally recognized for higher quality care and lower costs. Here Dr. Thompson and Urvashi Bhatnagar, DPT, MBA, author of The Sustainability Scorecard: How Firms can Implement and Profit from Unexpected Solutions, share the strategies and organizational mindset needed to advance sustainability in health care.
“We are extremely fortunate to have the opportunity to engage with Mark King in this particular phase of the company’s growth. My partner, Eric Wilhelm, and I hope to leverage Mark’s knowledge and experience to help realize the exciting vision we have had for more than a decade as individual business owners and for KMM Group.”
“The Liver-Chip detected nearly 7 out of every 8 drugs that proved hepatoxic in clinical use despite having been deemed to have an appropriate therapeutic window by animal models.”
Advances in medical devices and technology have had a profound effect on those with mild, moderate and severe hearing loss. Here, we take a closer look at how these technologies have evolved and what the future may hold.
The acquisition expands Veranex’s footprint for product design engineering services across the U.S., with combined company offices now in the Eastern, Central, and Western regions
The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.
